Madison-based TomoTherapy, maker of advanced radiation therapy solutions, announced that 82 studies examining the use of TomoTherapy(R) in the treatment of common, complex and rare tumors will be showcased at ESTRO 29, September 12-16, 2010, in Barcelona. The studies focus on the treatment system’s use on head and neck, prostate, breast and lung tumors, as well as blood cancers, mesothelioma and pediatric patients.

Scientists at the San Raffaele Scientific Institute in Milan, Italy compared TomoTherapy to other radiation therapy solutions, and reported that TomoTherapy produced the most homogeneous dose and conform dose distributions better than RapidArc(R). And researchers in Belgium and the Netherlands concluded that TomoTherapy treatment, at 6.6 minutes, was the fastest of all intensity-modulated radiation therapy (IMRT) techniques examined, while delivering the best homogeneity and equivalent or better OAR sparing.

TomoTherapy(SM) treatments have been found to have very low toxicities and side effects, even with delivery of escalated doses, and they produce minimal acute and moderate-late skin effects. In Lung Cancer Research, 42 percent of the patients had a complete metabolic response and 33 percent a partial response to the TomoTherapy treatment, while the patients experienced less toxicity and were able to complete treatment in 13 treatment sessions rather than 20.

These findings bode particularly well for aggressive cancers, such as mesothelioma, which are often fatal and come with a very short life expectancy. Mesothelioma treatment, which combines surgery, chemotherapy and radiotherapy, stands to benefit from a more effective form of radiotherapy that preserves more healthy tissue while demonstrably destroying a copious amount of cancerous tissue.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.